Contineum Therapeutics CTNM
NASDAQ CTNM
$16.70 -0.87 (-4.95%)
As of: Sep 4, 2026 · 3:59 PM EDT

Contineum Therapeutics (CTNM) Total Non-Current Liabilities (2023 - 2024)

Contineum Therapeutics (CTNM) posted quarterly Total Non-Current Liabilities of $14.8 million for Q4 2024, up 164.32% year-over-year from $5.6 million in Q1 2024, and up 154.58% quarter-over-quarter from $5.8 million in Q3 2024.

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo
Analysis

Contineum Therapeutics (CTNM) Total Non-Current Liabilities (2023 - 2024) Analysis & Trends

Contineum Therapeutics' Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $14.8 million for Q4 2024.

  • In Q4 2024, Total Non-Current Liabilities rose 164.32% year-over-year to $14.8 million; the TTM figure through Dec 2024 stood at $14.8 million (up 164.32% YoY), while the FY2024 annual figure was $14.8 million, up 164.32% from the prior year.
  • Total Non-Current Liabilities for Q4 2024 stood at $14.8 million, up from $5.8 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $14.8 million in Q4 2024, with the low at $3.9 million in Q2 2024.
Peer Set

Peer Comparison

All peers
# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 5.92 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 7.74 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 40.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 3.92 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 1.53 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 1.88 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 4.20 Bn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 9.32 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 1.17 Bn
10 Contineum Therapeutics 628.71 Mn 628.71 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 14.78 Mn
Sep 30, 2024 5.81 Mn
Jun 30, 2024 3.85 Mn
Mar 31, 2024 6.35 Mn
Dec 31, 2023 5.59 Mn